Personal Home Page

http://www.dukehealth.org/physicians/DC0792ECDB1504C6852571F600719502

Articles in Scholarly Journals [Incomplete List]

1. Rational Development of Targeted Cancer Therapies Using Biomarkers
   Laboratory Medicine, vol. 37, no. 8, pp. 482–489, 2008
2. Lapatinib Antitumor Activity Is Not Dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast Cancers
   Cancer Research, vol. 67, no. 3, pp. 1170–1175, 2007
3. A reciprocal tensin-3–cten switch mediates EGF-driven mammary cell migration
   Nature Cell Biology, vol. 9, no. 8, Article ID ncb1622, 8 pages, 2007
4. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells
   Proceedings of the National Academy of Sciences, vol. 104, no. 25, pp. 10607–10612, 2007
5. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
   Proceedings of the National Academy of Sciences, vol. 103, no. 20, pp. 7795–7800, 2006
6. Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers
   Cancer Research, vol. 66, no. 3, pp. 1640–1647, 2006
7. Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
   Journal of Clinical Oncology, vol. 23, no. 11, pp. 2502–2512, 2005
8. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
   Oncogene, vol. 24, no. 41, Article ID 1208774, 8 pages, 2005
9. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects
   Investigational New Drugs, vol. 23, no. 1, pp. 39–49, 2005
10. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
    Oncogene, vol. 23, no. 3, Article ID 1207166, 7 pages, 2004
11. A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon1
    International Journal of Radiation OncologyBiologyPhysics, vol. 58, no. 3, pp. 779–785, 2004
12. Breast Cancer Research and Treatment, vol. 77, no. 3, pp. 233–243, 2003
13. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
    Oncogene, vol. 21, no. 41, Article ID 1205794, 8 pages, 2002
14. Sensitization of tumor cells to Fas killing through overexpression of heat-shock transcription factor 1
    Journal of Cellular Physiology, vol. 183, no. 3, pp. 425–431, 2000
15. Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine
    Proceedings of the National Academy of Sciences, vol. 97, no. 13, pp. 7494–7499, 2000
16. Truncation of Sp1 transcription factor by myeloblastin in undifferentiated HL60 cells
    Journal of Cellular Physiology, vol. 175, no. 2, pp. 121–128, 1998
17. Activation signals regulate heat shock transcription factor 1 in human B lymphocytes
    Journal of Cellular Physiology, vol. 170, no. 3, pp. 235–240, 1997
18. 28-kDa Mammalian Heat Shock Protein, a Novel Substrate of a Growth Regulatory Protease Involved in Differentiation of Human Leukemia Cells
    Journal of Biological Chemistry, vol. 270, no. 3, pp. 1003–1006, 1995
19. Heat shock protein is a unique marker of growth arrest during macrophage differentiation of HL-60 cells
    Journal of Cellular Physiology, vol. 156, no. 3, pp. 619–625, 1993
20. Activation primes human B lymphocytes to respond to heat shock
    Journal of Experimental Medicine, vol. 170, no. 5, pp. 1763–1768, 1989